Press release
Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape @ Advanced Liver Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Advanced Liver Cancer Pipeline Report
* On March 09, 2026, AstraZeneca conducted a phase I/II study to evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.
* On March 05, 2026, Endeavor Biomedicines Inc. initiated a phase 2 study employing a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.
* DelveInsight's Advanced Liver Cancer pipeline report depicts a robust space with 50+ active players working to develop 52+ pipeline therapies for Advanced Liver Cancer treatment.
* The leading Advanced Liver Cancer Companies such as Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd. , and others.
* Promising Advanced Liver Cancer Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab , and others.
Stay informed about the cutting-edge advancements in Advanced Liver Cancer treatments @ Advanced Liver Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Liver Cancer Overview
Advanced liver cancer, characterized by its progression to later stages, represents a formidable medical challenge due to its propensity for metastasis and the intricate interplay of factors influencing disease progression. At this advanced stage, the cancer has typically infiltrated surrounding tissues and organs, disrupting normal liver function and potentially impacting vital bodily processes. Metastasis, often widespread by this point, can occur in various distant sites beyond the liver, including the lungs, bones, lymph nodes, and other regions, exacerbating the complexity of disease management.
Advanced Liver Cancer Emerging Drugs Profile
* Namodenoson: Can-Fite BioPharma
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson's mechanism of action is mediated via deregulation of the NF-?B and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.
* ADI-PEG20: Polaris Pharmaceuticals
Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumors, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumors that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 appears to show inhibitory effects on human melanomas and hepatocellular carcinomas. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.
* SRF388: Surface Oncology
SRF388 is a fully human IgG1 blocking antibody to IL-27 with potential to promote immune activation in the tumor microenvironment. The immunoregulatory cytokine IL-27 upregulates inhibitory immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines (eg, IFN?, TNFa). Currently, the drug is in the Phase II stage of development to treat Advanced liver cancer.
* TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. Currently, the drug is in the Phase I stage of development to treat Advanced liver cancer.
Learn more about Advanced Liver Cancer Drugs opportunities in our groundbreaking Advanced Liver Cancer Research and development projects @ Advanced Liver Cancer Unmet Needs [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Liver Cancer Companies
Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd, and others.
Advanced liver cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Advanced Liver Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Advanced Liver Cancer treatment by visiting our website @ Advanced Liver Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Advanced Liver Cancer Pipeline Report
* Coverage- Global
* Advanced Liver Cancer Companies- Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd. , and others.
* Advanced Liver Cancer Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.
* Advanced Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Read the full details of Advanced Liver Cancer Pipeline on our website @ Advanced Liver Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Advanced liver cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced liver cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Namodenoson: Can-Fite BioPharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced liver cancer Key Companies
* Advanced liver cancer Key Products
* Advanced liver cancer- Unmet Needs
* Advanced liver cancer- Market Drivers and Barriers
* Advanced liver cancer- Future Perspectives and Conclusion
* Advanced liver cancer Analyst Views
* Advanced liver cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-liver-cancer-clinical-trial-pipeline-shows-potential-with-active-contributions-from-50-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight here
News-ID: 4419509 • Views: …
More Releases from ABNewswire
Outdoor Living Retailers Widen Product Ranges as Backyard Kitchen Demand Enters …
Industry data shows homebuyers now rank four outdoor features among the thirteen most-wanted home amenities, prompting e-commerce sellers to consolidate fragmented product categories under single storefronts. Culinary Wilderness, a Staten Island-based online retailer, has expanded from barbecue equipment into more than 50 outdoor living categories including kitchen islands, refrigeration, fire features, and shade structures.
When the National Association of Home Builders published its 2024 "What Home Buyers Really Want" report -…
The Boulder Group's Randy Blankstein and Jimmy Goodman Named 2026 Crexi Platinum …
Net Lease Firm's Partners Win Industry Recognition
The Boulder Group, a net leased investment brokerage firm, announced that Randy Blankstein, President, and Jimmy Goodman, Partner, have each been named 2026 Crexi Platinum Award winners. The Crexi Platinum Awards recognize the highest performing commercial real estate professionals on the Crexi platform, placing Blankstein and Goodman among the top tier of investment sales brokers in the United States.
Crexi is one of the nation's…
Atopic Dermatitis Pipeline 2026: FDA Approvals and Clinical Trials Landscape wit …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Complement 3 Glomerulopathy Market: Strong Pharma Growth Forecast Through 2034 - …
The Key Complement 3 Glomerulopathy Companies in the market include - NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others.
DelveInsight's "Complement 3 Glomerulopathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Complement 3 Glomerulopathy, historical and forecasted epidemiology as well as the Complement 3 Glomerulopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
